b'Innovate UK ICURe ProgrammeIMPACT IN MOTIONWe are proud to share the progress and achievements of participants who have taken part in our biofilm-focused Innovate UK ICURe (Innovation to Commercialisation of University Research) programmes, delivered by SETsquared. These initiatives continue to support early-career researchers and entrepreneurs in transforming their ideas into market-ready innovations. The past year has seen our participants advance their technologies, secure new partnerships, attract investment and establish thriving ventures. Their journeys demonstrate the lasting impact of ICURe in driving innovation, fostering commercial skills, and accelerating the translation of research into real-world solutions.Dr Anish Parmar and Dr Ishwar Singh Dr Anish Parmar and Dr Ishwar Singh participated in the Biofilms ICURe Sprint in 2022 to explore the market potential of their synthetic teixobactins - a novel antibiotic class developed specifically to tackle antimicrobial resistance (AMR). These compounds offer distinct advantages: they target essential bacterial lipids, making resistance development highly unlikely, and are produced via a robust, cost-effective, and scalable synthetic platform suitable for automated manufacturing. In 2024, the team secured follow-on funding from Innovate UK to establish a spin-out. In July 2025, their work earned them the Health Category prize at the Royal Society of Chemistry (RSC)s Emerging Technologies Competition - a prestigious nationalDr Ishwar Singh and Dr Anish Parmar award judged by leaders from major global companies including GSK,accepting the Health Category prize at the Unilever and Johnson Matthey. The award provides both fundingRSC Emerging Technologies Competition and national recognition for early-stage scientific innovation withaward event. Image by the RSC.high potential for real-world impact. The team is now preparing for commercialisation and actively seeking further partnerships and funding to translate their breakthrough into clinical solutions.22'